ライフサイエンスコーパス: RR

1 RR aqueous emulsions were examined for cell cytotoxicity

2 RR of ASD increased by GA, from 40 to 24 weeks and from

3 RR of death comparing patients with recent systemic anti

4 RR produces a binary result that, when positive, is used

5 ates (medical therapy, 26.1% vs. SLT, 19.0%; RR, 1.37; 95% CI, 1.33-1.42; P < 0.001).

6 57] and 30% [16/53], respectively; P = .043; RR 1.63, 95% CI 1.0-2.65).

7 pital for more than one day [26.4% vs.30.1%, RR (95%CI):0.88(0.82-0.94), P<.001].

8 ession (medical therapy, 9.9% vs. SLT, 7.1%; RR, 1.39; 95% CI, 0.95, 2.03; P = 0.0928).

9 5% CI, -67% to -3%] and 12 trials, n = 1599; RR, 0.73 [95% CI, 0.62 to 0.85]; ARD, -18% [95% CI, -26%

10 sition metal species can maintain high CO(2) RR activity with tunable CO/H(2) ratios.

11 H/NbN are critical to achieving higher CO(2) RR activity.

12 mation of PdH in Pd/NbN and Pd/C under CO(2) RR conditions, whereas the Pd in Pd/VN is not fully tran

13 ation of a core-shell structure during CO(2) RR for FeAg NPs was inferred from the analysis of the op

14 nder the development of photocatalytic CO(2) RR owing to the lack of effective catalysts.

15 ocal pH probe allows us to investigate CO(2) RR without the interference of additional probe molecule

16 ven photocatalytic reduction of CO(2) (CO(2) RR) into chemical fuels is a promising route to enrich e

17 hange in the CO(2) reduction reaction (CO(2) RR) pathway.

18 ctrochemical CO(2) reduction reaction (CO(2) RR) to yield synthesis gas (syngas, CO and H(2) ) has be

19 n (ORR), the CO(2) reduction reaction (CO(2) RR), the nitrogen reduction reaction (NRR), and the oxyg

20 e above-mentioned reactions (HER, ORR, CO(2) RR, NRR, and OER), the current challenges faced by these

21 on peak shifts by -86+/-2 mV/pH during CO(2) RR, which can be used to directly quantify the change in

22 lectrocatalysts to produce syngas from CO(2) RR.

23 ith high FE and high conversion rate in CO(2)RR and also make direct use of dilute CO(2) feedstocks.

24 dehyde, a reactive intermediate in both CO(2)RR and CORR, via combined isotopic labeling and in situ

25 the catalyst surface under the working CO(2)RR conditions, which greatly facilitates the CO(2) to me

26 (MOFs), thereby allowing us to improve CO(2)RR electrocatalysis.

27 lar chemistry to control the binding of CO(2)RR intermediates on metal catalysts encapsulated inside

28 tate of Cu catalyst surfaces during the CO(2)RR remains a matter of debate.

29 port an all-solid-state electrochemical CO(2)RR system for continuous generation of high-purity and h

30 result of this strategy, we report the CO(2)RR to ethylene with a Faradaic efficiency of 72 per cent

31 ectrochemical CO(2) reduction reaction (CO(2)RR) often exhibit a high degree of electronic delocaliza

32 ectrochemical CO(2) reduction reaction (CO(2)RR) to liquid fuels is currently challenged by low produ

33 ectrochemical CO(2) reduction reaction (CO(2)RR) using Cu-based catalysts holds great potential for p

34 ectrochemical CO(2) reduction reaction (CO(2)RR), control over the binding of intermediates is key fo

35 electrocatalysts is dynamic during the CO(2)RR, and emphasize the importance of in situ characteriza

36 Besides CO(2)RR, there is an additional strong demand for benign elec

37 in the pursuit of materials design for CO(2)RR.

38 > 300 mg/m(2) of lomustine (300-600 mg/m(2): RR, 4.21 [95% CI, 1.61 to 11.01] and >= 600 mg/m(2): RR,

39 [95% CI, 1.61 to 11.01] and >= 600 mg/m(2): RR, 9.12 [95% CI, 2.75 to 30.24]) were all independent r

40 The sample included 1563 subjects (24% RR).

41 regression analysis showed MSM aged 21 - 25 (RR: 3.199, 95% CI: 1.832, 5.586) and not linked to care

42 nterval [CI] 1.245-1.263; P < .001) and 26% (RR 1.260, 95% CI 1.257-1.264; P < .001) increases in syp

43 py in SOT vs. non-SOT patients (37% vs. 27%; RR [95% CI]: 1.34 [0.97-1.85]).

44 in 1.1% (24/2,280) versus 1.9% (46/2,273), (RR 0.52 [95% CI 0.32 to 0.85], p-value 0.009, RD -97/10,

45 95% confidence interval (CI): 1.05 to 2.38]; RR per 1-SD increment: 1.33 [95% CI: 1.06 to 1.67]).

46 the vaccine and placebo groups, 53% vs. 45% (RR 1.16, 95% CI .87-1.6, P=.29).

47 , .1-.5]), abdominal surgery (3.9% vs 17.5%; RR, 0.2 [95% CI, .09-.5]), and total parenteral nutritio

48 d total parenteral nutrition (3.9% vs 22.5%; RR, 0.2 [95% CI, .07-.4]).

49 up (33.7%) than in the control group (26.5%; RR, 1.26; 95% CI, 1.01-1.52), as were adenomas of 6 to 9

50 (71.7%) than sleeve gastrectomy (SG; 64.5%; RR 0.92, confidence interval (CI) 0.86-0.99) and adjusta

51 CI: 1.3, 3.7), RR = 1.4 (95% CI: 0.8, 2.5), RR = 1.7 (95% CI: 1.0, 2.9).

52 risk of drug use relapse (4 trials, n = 567; RR, 0.75 [95% CI, 0.59 to 0.82]; ARD, -35% [95% CI, -67%

53 99) and adjustable gastric band (AGB; 33.6%; RR 0.45, CI 0.34-0.60; p < 0.001).

54 ch was non-inferior (282 [68%] vs 269 [63%], RR 1.08, 0.98-1.19; p(non-inferiority)=0.0049).

55 th the clinic group (306 [74%] vs 269 [63%], RR 1.18, 95% CI 1.07-1.29; p(superiority)=0.0005) and th

56 DVD achieved a 66% RR and a 55% VGHR rate.

57 [(RR = 0.92, 95% CI 0.69-1.23, I(2) = 67%), (RR = 1.11, 95% CI 0.26-4.69, I(2) = 85%), (RR = 1.21, 95

58 14); the DASH diet was associated with a 68% RR reduction (OR: 0.32; 95% CI: 0.14, 0.76; Ptrend = 0.0

59 relative risk (RR) = 2.2 (95% CI: 1.3, 3.7), RR = 1.4 (95% CI: 0.8, 2.5), RR = 1.7 (95% CI: 1.0, 2.9)

60 s (rate ratio (RR): 1.36, 95% CI: 1.06-1.72; RR: 1.28, 95% CI: 1.01-1.63, respectively) and at-fault

61 ,72; 95% CI -34,65% to -26,79%) and EASI-75 (RR 3.09; 95% CI 2.45 to 3.89), pruritus (RR 2.96; 95% CI

62 (RR = 1.11, 95% CI 0.26-4.69, I(2) = 85%), (RR = 1.21, 95% CI 0.70-2.01, I(2) = 95%), and (RR = 0.98

63 t crashes only (RR: 1.50, 95% CI: 1.16-1.93; RR: 1.38, 95% CI: 1.07-1.78, respectively).

64 with experience transplanting <23 SLs had a RR of 1.43 (1.21-1.75).

65 ident in models adjusted for adiposity (AAM: RR = 0.97 per year, 95% CI 0.95-0.98, p < 0.001, 12 esti

66 with improved survival (51% vs 14%, adjusted RR for mortality 0.57, 95% CI [0.35-0.93]; p=0.0029).

67 d at least 1 serious adverse event (adjusted RR, 1.72 [95% CI, 0.7 to 4.3]).

68 decreased P falciparum prevalence (adjusted RR [ARR] 0.46, 95% CI 0.40-0.53; p<0.0001; 15 648 indivi

69 lycemia (RR) 5.7 (p = 0.004), ICU admission (RR) 14 (p < 0.0001), receipt of IV fluids (RR) 3.2 (p =

70 BMI normalized from childhood to adulthood: RR was 2.04 (95% CI: 0.93, 4.47) for gestational hyperte

71 ns were associated only with increasing age (RR, 1.03; 95% CI: 1.01, 1.05).

72 mplete CIV control versus ondansetron alone (RR, 1.28; 95% CI, 1.09 to 1.50).

73 , we estimated 146 996 excess deaths with an RR of 1.5, 293 991 with an RR of 2.0, and 587 982 with a

74 ss deaths with an RR of 1.5, 293 991 with an RR of 2.0, and 587 982 with an RR of 3.0.

75 3 991 with an RR of 2.0, and 587 982 with an RR of 3.0.

76 family history of AD was associated with an RR of 6.56 (95% CI: 4.92 to 8.77) for AD.

77 irst-degree relatives was associated with an RR of 6.82 (95% confidence interval [CI]: 5.12 to 9.07).

78 ence interval [CI] = 1.10-11.1, p = 0.03 and RR = 3.28, 95% CI = 1.03-10.45, p = 0.045, respectively)

79 R: 1.19; P = 0.045; CI 95% 1.00 to 1.40; and RR: 1.20; P = 0.063; CI 95% 0.99 to 1.45 in the adjusted

80 nce rates (RR: 2.09; 95% CI 1.39 to 2.95 and RR: 2.22; 95% CI 1.46 to 3.17, respectively).

81 ficient were more important than N input and RR(NUE) in improving RR(Y).

82 l equation model showed that water input and RR(WP) with the higher coefficient were more important t

83 ement is found in the values of R(s), n, and RR by 3, 1.7, and 19 times, respectively, for Ag/F8-CdSe

84 = 1.21, 95% CI 0.70-2.01, I(2) = 95%), and (RR = 0.98, 95% CI 0.76-1.27, I(2) = 85% )] respectively.

85 adjusted OR = 0.72, 95% CI: 0.53, 0.99) and (RR ratio = 0.62, 95% CI: 0.39, 1.00), respectively.

86 However, as RR increases and SpO(2) decreases with elevation, these

87 .02-1.75), and cysts with edema at baseline (RR 1.39; 95% C.I. 1.05-1.85).

88 reduced, and the time series of beat-to-beat RR intervals (RRIs) become highly non-stationary.

89 % CI 1.13-2.26; p = 0.008) and all bleeding (RR 1.49; 95% CI 1.10-2.01; p = 0.010).

90 Conversely, the risks of major bleeding (RR, 1.36; 95% CI, 0.55-3.35) and CRNMB (RR, 1.63; 95% CI

91 Both RR and CDR remained improved compared with DM for 5 year

92 nce interval [CI], 7.0, 68.8) and with BSIs (RR, 6.0; 95% CI, 2.5, 14.4).

93 , 8.73 to 43.48]), having received busulfan (RR, 4.53 [95% CI, 2.10 to 9.77]), or > 300 mg/m(2) of lo

94 ke an interaction critical for activation by RR-RJW100.

95 s associated with peritoneal carcinomatosis (RR: 5.9; 95% CI: 3.8, 9.2; P = .03).

96 and participants from the Northeast centres (RR(adj) 2.35, 95% CI [1.11-4.95], p-value 0.034) were in

97 % per 1 mmol/L reduction in LDL cholesterol (RR 0.74 [95% CI 0.61-0.89]; p=0.0019), with no statistic

98 R), 9.37 (95% CI: 2.17-40.4, p = 0.003); CHW RR, 6.85 (1.15-40.9, p = 0.035).

99 relative risk for all PC subtypes combined (RR, 2.30; 95% CI, 2.22 to 2.40), followed by HBOC and LS

100 ients with acute-phase complete CIV control (RR, 1.19; 95% CI, 1.06 to 1.34) and in those who receive

101 trongly reduced the risk of IGRA conversion (RR, 0.56 [95% CI, .40-.77]; P < .001).

102 ing (RR, 1.36; 95% CI, 0.55-3.35) and CRNMB (RR, 1.63; 95% CI, 0.73-3.64) were nonsignificantly highe

103 p = 0.31), though had higher risk of CRNMB (RR 1.60; 95% CI 1.13-2.26; p = 0.008) and all bleeding (

104 s Q1], 1.70; 95% CI, 1.07-2.71) and current (RR Q4 vs Q1, 1.70; 95% CI, 1.07-2.71) diagnosed asthma,

105 ignificant decrease of the resistant CYP6P9a-RR genotype was observed after ten generations (chi(2) =

106 -6 d, RR = 0.96, 95% CI = 0.68-1.35; 7-14 d, RR = 0.91, 95% CI = 0.49-1.46; and >14 d, RR = 1.22, 95%

107 d, RR = 0.91, 95% CI = 0.49-1.46; and >14 d, RR = 1.22, 95% CI = 0.59-2.07).

108 -6 d, RR = 1.31, 95% CI = 0.99-1.73; 7-14 d, RR = 1.52, 95% CI = 1.00-2.18], compared with no opioid

109 = 319, 5%) with opioid prescription [1-3 d, RR = 1.00, 95% confidence interval (CI) = 0.74-1.32; 4-6

110 f opioid prescribed (reference 1-3 d; 4-6 d, RR = 0.96, 95% CI = 0.68-1.35; 7-14 d, RR = 0.91, 95% CI

111 confidence interval (CI) = 0.74-1.32; 4-6 d, RR = 1.31, 95% CI = 0.99-1.73; 7-14 d, RR = 1.52, 95% CI

112 cated perineal wound healing within 30 days (RR 1.30; 95% CI 0.92-1.82), chronic perineal sinus (RR 1

113 ]; P<0.001) and major amputation at 90 days (RR, 0.23 [95% CI, 0.21-0.26]; P<0.001).

114 nstable CAD, PCI also reduced cardiac death (RR, 0.69 [95% CI, 0.53-0.90]; P=0.007) and MI (RR, 0.74

115 R, 0.98 [95% CI, 0.87-1.11]), cardiac death (RR, 0.89 [95% CI, 0.71-1.12]; P=0.33), or MI (RR, 0.96 [

116 of deaths and had a strong same-day effect (RR, 1.08; 95% CI, 1.03 to 1.12) and cumulative effect ov

117 control groups had more pulmonary embolism (RR 2.22, 95% CrI 1.78-2.89, p<0.0001) and fatal pulmonar

118 by resonance Raman (RR) and surface enhanced RR (SERR) spectroscopy, and the electrocatalytic propert

119 rease in the end-of-life recycling rate (EOL-RR) could contribute to minimizing the overall energy co

120 isode (RR-any, primary), depressive episode (RR-dep) and manic/hypomanic/mixed episode (RR-mania), di

121 (RR-dep) and manic/hypomanic/mixed episode (RR-mania), discontinuation, mortality, and individual ad

122 recurrence/relapse rate of any mood episode (RR-any, primary), depressive episode (RR-dep) and manic/

123 ally pure RJW100 derivatives: they establish RR-RJW100 as the stronger LRH-1 agonist and identify a p

124 Poisson regressions were applied to estimate RR and 95% CI of incident diabetes associated with indiv

125 without LNS attenuated the effect estimate (RR: 0.82; 95% CI: 0.61, 1.10).

126 (RR) 14 (p < 0.0001), receipt of IV fluids (RR) 3.2 (p = 0.0151) and need for surgery (RR) 6.6 (p =

127 We estimated smooth percentiles for RR and SpO(2) that varied by age and site using generali

128 nd paliperidone outperformed the placebo for RR-any.

129 ine, and quetiapine outperformed placebo for RR-dep.

130 ine+LIT/VAL outperformed placebo+LIT/VAL for RR-mania.

131 oncentration in GCF was associated with GDM (RR: 1.19; P = 0.045; CI 95% 1.00 to 1.40; and RR: 1.20;

132 group and 294 occurred in the placebo group (RR 0.74; 95% CI 0.58-0.94, p=0.013).

133 group and 451 occurred in the placebo group (RR 0.80, 95% CI 0.64-1.00, p=0.050).

134 the CADe group vs 5.8% in the control group; RR, 1.78; 95% CI, 1.09-2.86), regardless of morphology o

135 Mortality was comparable in both groups (RR, 0.96; 95% CI, 0.68-1.36).

136 tween the standard care (SC) and HCQ groups (RR = 0.99, 95% CI 0.61-1.59, I(2) = 82%), meta-regressio

137 s in control groups versus treatment groups (RR 2.74, 95% CrI 2.32-3.31, p<0.0001).

138 1 to 9.86]), pituitary irradiation (5-20 Gy: RR, 4.24 [95% CI, 1.98 to 9.06]; 20-40 Gy: RR, 10.16 [95

139 : RR, 4.24 [95% CI, 1.98 to 9.06]; 20-40 Gy: RR, 10.16 [95% CI, 5.18 to 19.94]; and >= 40 Gy: RR, 19.

140 10.16 [95% CI, 5.18 to 19.94]; and >= 40 Gy: RR, 19.48 [95% CI, 8.73 to 43.48]), having received busu

141 89 [95% CI, 0.81-0.99], P=0.03; hemorrhagic: RR, 0.60 [95% CI, 0.54-0.68], P<0.0001) were also lower

142 tile) at both time points showed the highest RR of 1.79 (95% CI: 1.08 to 2.96) for CHD as compared wi

143 he risk of MCI was increased for <= 5 hours (RR = 2.86, 1.24-6.60, reference:7 to <8 hours).

144 sociated with the presence of any 9v HR-HPV (RR, 4.3 [95% CI, 1.6-11.5]; P < .001).

145 BMIZ, elevated BP, and hypercholesterolemia (RR, 1.43; P = .02).

146 ce interval [CI]: 1.01, 1.03), hypertension (RR, 1.46; 95% CI: 1.06, 2.02), diabetes mellitus (RR, 1.

147 ive Risk (RR) 2.88 (p = 0.03), hypoglycemia (RR) 5.7 (p = 0.004), ICU admission (RR) 14 (p < 0.0001),

148 Concurrent veliparib did not improve RR.

149 ortant than N input and RR(NUE) in improving RR(Y).

150 ST-segment-elevation myocardial infarction (RR, 0.84 [95% CI, 0.69-1.04]; P=0.11); non-ST-segment-el

151 001), and for each stroke subtype (ischemic: RR, 0.89 [95% CI, 0.81-0.99], P=0.03; hemorrhagic: RR, 0

152 oholic PVI, although uncertainty was larger [RR 0.51 (95% confidence interval 0.21, 1.27)].

153 ong women exposed to gabapentin either late (RR, 1.28 [1.08-1.52], p < 0.01) or both early and late i

154 nificantly lower with DOACs than with LMWHs (RR, 0.68; 95% CI, 0.39-1.17).

155 nificantly lower with DOACs than with LMWHs (RR, 0.86; 95% CI, 0.60-1.23).

156 d risk of ever (risk ratio [RR] high vs low [RR Q4 vs Q1], 1.70; 95% CI, 1.07-2.71) and current (RR Q

157 0.001], while risk among females was lower [RR 0.89, 95% CI: 0.83 to 0.96, p-value = 0.002].

158 ted risk of SGA comparing middle vs. lowest (RR, 2.34; 95% CI: 1.02, 5.35) and highest vs. lowest (RR

159 95% CI: 1.02, 5.35) and highest vs. lowest (RR, 2.47; 95% CI: 1.09, 5.58) exposure groups.

160 .40), followed by HBOC and LS (both with 1 < RR < 2 and statistically significant).

161 Compared to India, mean RR was 9.6 breaths per min higher in Guatemala, 12.1 bre

162 96; 95% CI 2.37 to 3.70), rescue medication (RR 3.46; 95% CI 2.79 to 4.30), sleep disturbance (MD -7.

163 .46; 95% CI: 1.06, 2.02), diabetes mellitus (RR, 1.67; 95% CI: 1.20, 2.33), and a higher multivariabl

164 d for short-term and spatial working memory (RR = 1.25, 95% CI: 0.98, 1.58).

165 es, n = 852,268, I2 = 51.8%; early menarche: RR = 1.19, 95% CI 1.11-1.28, p < 0.001, 21 estimates, n

166 1.2, 2.4; P = .002) and osseous metastases (RR: 1.9; 95% CI: 1.6, 2.3; P = .02); RB1 mutation (seen

167 , 0.69 [95% CI, 0.53-0.90]; P=0.007) and MI (RR, 0.74 [95% CI, 0.62-0.90]; P=0.002).

168 R, 0.89 [95% CI, 0.71-1.12]; P=0.33), or MI (RR, 0.96 [95% CI, 0.86-1.08]; P=0.54).

169 eased risk of disproportionate microcephaly (RR 10.3, 95% CI 2.0-52.6).

170 the cyst level were cysts larger than 14 mm (RR 1.34; 95% C.I. 1.02-1.75), and cysts with edema at ba

171 Among YLPHIV, CD4 count >500 cell/mm3 (RR, 1.04; P = .76), VL (RR, 1.01; P = .78), and current

172 lar reduction was seen in cardiac mortality (RR: 0.53; 95% CI: 0.33 to 0.85; p = 0.009).

173 s associated with a lower risk of mortality (RR, 0.45 [95% CI, 0.41-0.50]; P<0.001) and major amputat

174 or stable CAD, PCI did not reduce mortality (RR, 0.98 [95% CI, 0.87-1.11]), cardiac death (RR, 0.89 [

175 exposure to sporozoite-infected mosquitoes (RR, 1.24; 95% CI, 1.11-1.38).

176 cated that iNPWT also reduced skin necrosis (RR 0.49, 95% CI: 0.33-0.74), seroma (RR 0.43, 95% CI: 0.

177 rol) of yield (RR(Y)), WP (RR(WP)), and NUE (RR(NUE)), respectively.

178 The role of RR phenolics in regulating glucose homeostasis was decip

179 63, respectively) and at-fault crashes only (RR: 1.50, 95% CI: 1.16-1.93; RR: 1.38, 95% CI: 1.07-1.78

180 nctional dependence at 3 months after onset (RR per year 0.983; 95% CI 0.968-0.998; p = 0.002 for tre

181 fold increased risk of microcephaly overall (RR 5.1, 95% CI 1.2-22.5) and a ten-fold increased risk o

182 al weight gain between 20 and 27 weeks <p10 (RR(adj) 2.04, 95% CI [1.23-3.38], p-value 0.018) and par

183 fully saturated sphingoid-fatty acid pairs (RR Q4 versus Q1 = 3.15; 95% CI: 1.75, 5.67; P-trend <0.0

184 n and 754 (13.1%) of those who took placebo (RR 0.89 [95% CI 0.81 to 0.98], p=0.012).

185 the null [e.g., for an IQR increase in PNC, RR = 1.17 (95% CI: 1.05, 1.31) vs. 1.06 (95% CI: 0.95, 1

186 eta-analysis including 5 studies, the pooled RR (95% CI) for CAD in the lowest compared with the high

187 ent T2D cases), for each 1 egg/d, the pooled RR of T2D was 1.07 (95% CI: 0.99, 1.15; I2 = 69.8%).

188 < 0.01) or both early and late in pregnancy (RR, 1.22 [1.09-1.36], p < 0.001), SGA among women expose

189 0.05), or both early and late in pregnancy (RR, 1.32 [1.08-1.60], p < 0.01), and NICU admission amon

190 gabapentin both early and late in pregnancy (RR, 1.35 [1.20-1.52], p < 0.001).

191 d with lower risk of antibiotic prescribing (RR, 0.4; 95% CI 0.2-0.8; P = .01), though collinearity b

192 66; P < 0.0001, n = 1399, I = 53% probiotics RR: 0.65; 95% CI: 0.53-0.80; P < 0.0001, n = 1324, I = 1

193 days; P = 0.005, n = 535, I = 91% probiotics RR: -0.65; 95% CI: -2.03-0.72; P = 0.35, n = 294, I = 65

194 75 (RR 3.09; 95% CI 2.45 to 3.89), pruritus (RR 2.96; 95% CI 2.37 to 3.70), rescue medication (RR 3.4

195 pi-PTB (RR(adj) 8.12, 95% CI [2.54-25.93], p-value 0.007), mater

196 site infection when compared to aqueous PVI [RR 0.49 (95% confidence interval 0.24, 1.02)] and also t

197 ized state are addressed by resonance Raman (RR) and surface enhanced RR (SERR) spectroscopy, and the

198 Recall rate (RR) percentage, cancer detection rate (CDR) per 1000 wom

199 DD achieved a remission rate (RR) of 64% and a very good hematologic remission (VGHR)

200 re based on thresholds for respiratory rate (RR) and oxyhaemoglobin saturation (SpO(2)) recommended b

201 with AGB having the lowest cessation rates (RR 0.55, CI 0.40-0.74; p < 0.001).

202 ely, and a 12% reduction in chlamydia rates (RR: 0.884, 95% CI 0.883-0.885; P < .001).

203 n local general population prevalence rates (RR: 2.09; 95% CI 1.39 to 2.95 and RR: 2.22; 95% CI 1.46

204 Low recycling rates (RR, 13-20%) and dependence on virgin plastic, representi

205 cardiovascular hospitalization [rate ratio (RR) 1.25, 95% CI: 1.16 to 1.35, p-value < 0.001], while

206 when considered for all crashes (rate ratio (RR): 1.36, 95% CI: 1.06-1.72; RR: 1.28, 95% CI: 1.01-1.6

207 We meta-analysed the risk ratio (RR) for major vascular events (a composite of cardiovasc

208 ns compared with SpO2 >= 90%: HC Risk Ratio (RR), 9.37 (95% CI: 2.17-40.4, p = 0.003); CHW RR, 6.85 (

209 ) occurred in the placebo group (rate ratio [RR] 0.79, 95% CI 0.62-1.01, p=0.059).

210 f control participants (adjusted rate ratio [RR] 2.10; 95% CI 1.75-2.53, P < 0.001), and their sexual

211 s not statistically significant (rate ratio [RR] = 0.56 [95% CI 0.28-1.13; P = .11]).

212 1.2 cases per 1000 person-years; rate ratio [RR], 8.12; 95% CI, 3.81 to 17.27; rate difference, 8.6 c

213 ted with the progression of WMH (rate ratio [RR]: 1.14; 95% CI: 1.02 to 1.27).

214 ntly reduced the risk of stroke (risk ratio [RR] 0.24, 95% CI 0.08-0.68).

215 ions in P falciparum prevalence (risk ratio [RR] 0.27, 95% CI 0.17-0.44), anaemia (0.77, 0.65-0.91),

216 r than for controls (60% vs 25%, risk ratio [RR] for mortality 0.54, 95% CI [0.40-0.70]; p<0.0001).

217 ted with increased risk of ever (risk ratio [RR] high vs low [RR Q4 vs Q1], 1.70; 95% CI, 1.07-2.71)

218 d total antibiotic use (adjusted risk ratio [RR] per doubling of urine culturing, 1.21; 95% confidenc

219 the SLT group (26.2% vs. 16.9%; risk ratio [RR], 1.55; 95% confidence interval [CI], 1.23-1.93; P <

220 1), and the case-fatality ratio (risk ratio [RR], 16.5; 95% CI, 13.7-19.8) associated with RSV-ALRI w

221 s with nonbacteremia infections (risk ratio [RR], 21.9; 95% confidence interval [CI], 7.0, 68.8) and

222 Rate ratios (RR) and 95% confidence intervals (CIs) were calculated c

223 hospitalizations for cardiovascular reasons (RR, 0.91 [95% CI, 0.85-0.97], P=0.004), stroke (RR, 0.80

224 The righting reflex (RR) is frequently used to assess level of arousal and ap

225 neal complication necessitating reoperation (RR 1.06; 95% CI 0.80-1.42) as well.

226 Mini-Symposia series in May and June; Rino (RR) was one of the scientific organizers of the Transfor

227 showed no difference in major bleeding risk (RR 1.31; 95% CI 0.78-2.18; p = 0.31), though had higher

228 s n-3 PUFAs were associated with lower risk (RR Q4 vs Q1, 0.59; 95% CI, 0.33-1.03) of current diagnos

229 following abdominal surgery [relative risk (RR) 0.56; 95% confidence interval (CI) 0.46-0.69; P < 0.

230 duced SSI [28 RCTs, n = 4398, relative risk (RR) 0.61, 95% confidence interval [CI]: 0.49-0.76, P < 0

231 ity: unrevascularized post-MI relative risk (RR) 0.68 (95% CI, 0.45-1.03); P=0.07; multivessel diseas

232 s for mortality were male sex Relative Risk (RR) 2.88 (p = 0.03), hypoglycemia (RR) 5.7 (p = 0.004),

233 presence of lacunar infarcts [relative risk (RR) = 1.024 (95% CI: 1.004, 1.045) per 10% increase in c

234 ory and associative learning (relative risk (RR) = 1.38, 95% confidence interval (CI): 1.08, 1.75), a

235 r risk of detectable cadmium, relative risk (RR) = 2.2 (95% CI: 1.3, 3.7), RR = 1.4 (95% CI: 0.8, 2.5

236 ded if they reported adjusted relative risk (RR) estimates and 95% confidence intervals (CIs) of abdo

237 lised linear models to obtain relative risk (RR) estimates and associated confidence intervals.

238 d noninferiority margin was a relative risk (RR) of 0.90.

239 cide-treated net (ITN) use on relative risk (RR) of confirmed malaria.

240 als that introduced CCRT, the relative risk (RR) of FTR was 0.84, (95% confidence interval (CI) 0.78-

241 iority was done to test for a relative risk (RR) of more than 0.95.

242 ,281] versus 1.0% [23/2,280]; relative risk [RR] 0.43 [95% confidence interval [CI] 0.21 to 0.91], p-

243 rtemisinin-piperaquine group (relative risk [RR] 0.64, 95% CI 0.39 to 1.04).

244 s (40% and 43%, respectively; relative risk [RR] 0.92; 95% confidence interval [CI]: 0.70-1.22).

245 tion was associated with 25% (relative risk [RR] 1.254, 95% confidence interval [CI] 1.245-1.263; P <

246 OC arm (34%, 18/53; P < .001; relative risk [RR] 2.48, 95% CI 1.54-3.95), and the proportion of parti

247 cognitive decline at 3 years (relative risk [RR] = 3.49, 95% confidence interval [CI] = 1.10-11.1, p

248 ith an increased risk of CHD (relative risk [RR] in the top tertile: 1.58 [95% confidence interval (C

249 ng malignancy (7.0% vs 29.4%; relative risk [RR], 0.2 [95% confidence interval {CI}, .1-.5]), abdomin

250 of a positive baseline IGRA (relative risk [RR], 0.89 [95% confidence interval {CI} .83-.97]; P = .0

251 the time of cancer treatment (relative risk [RR], 0.91 [95% CI, 0.88 to 0.95] by year of age), small

252 Increasing age (relative risk [RR], 1.02; 95% confidence interval [CI]: 1.01, 1.03), hy

253 he presence of any 9v HR-HPV (relative risk [RR], 1.8 [95% confidence interval {CI}, 1.3-2.6]; P < .0

254 ociated with lymphadenopathy (relative risk [RR]: 1.7; 95% confidence interval [CI]: 1.2, 2.4; P = .0

255 Relative risks (RR) of developing MCI when exposed to sleep characterist

256 tion at 1-year post-surgery: relative risks (RR) summarising predictive factors were determined, unad

257 icacy of interventions using relative risks (RR).

258 re reported in the HCQ group than in the SC (RR = 3.14, 95% CI 1.58-6.24, I(2) = 0).

259 Q did not differ significantly from the SC [(RR = 0.92, 95% CI 0.69-1.23, I(2) = 67%), (RR = 1.11, 95

260 mic and lifestyle factors, a ceramide score (RR Q4 versus Q1 = 2.40; 95% CI: 1.24, 4.65; P-trend = 0.

261 ifestations of Arterial Disease risk score) (RR, 1.01; 95% CI: 1.00, 1.02) were associated with a hig

262 t diagnosis (<= 2 standard deviation scores; RR, 6.74 [95% CI, 4.61 to 9.86]), pituitary irradiation

263 crosis (RR 0.49, 95% CI: 0.33-0.74), seroma (RR 0.43, 95% CI: 0.32-0.59), and length of stay (pooled

264 wing surgery was comparable for RYGB and SG (RR 0.97, CI 0.90-1.04), with AGB having the lowest cessa

265 ; 95% CI 0.92-1.82), chronic perineal sinus (RR 1.08; 95% CI 0.53-2.20), and pelviperineal complicati

266 showed an increased risk of IFD in smokers (RR 1.41 [95% confidence interval 1.09-1.81]; P = .008).

267 n = 2516; 80.7% vs 84.1% continued smoking; RR, 0.97 [95% CI, 0.93-1.01]).

268 llent peak potential difference (DeltaEp (SS-RR) = 108 mV) between ETB isomers using SWV showing a cl

269 A Vip3Aa-resistant strain (RR) derived from the F(2) screen showed a high level of

270 0.91 [95% CI, 0.85-0.97], P=0.004), stroke (RR, 0.80 [95% CI, 0.72-0.88], P<0.0001), and for each st

271 The summary RR for high vs. low physical activity was 0.70 (95% CI:

272 (RR) 3.2 (p = 0.0151) and need for surgery (RR) 6.6 (p = 0.0001).

273 s compared with probiotics alone (synbiotics RR: 0.46; 95% CI: 0.33-0.66; P < 0.0001, n = 1399, I = 5

274 T-segment-elevation acute coronary syndrome (RR, 0.84 [95% CI, 0.72-0.97]; P=0.02).

275 From 278 MDR-TB/RR-TB index case households, 743 HHCs were enrolled; the

276 The high percentage of HHCs of MDR-TB/RR-TB index cases willing to take hypothetical MDR TPT p

277 We find that RR is an unreliable metric for arousal/recovery of consc

278 The RR for arm A was 74.1% and 65.2% for arm B (P = .55); bo

279 mes were self-reported, and we estimated the RR (95% CI) of pre-eclampsia and GHTN with log-binomial

280 stimated by propagating uncertainty from the RR meta-estimates, prevalence of household air pollution

281 4 arm versus 71% (95% CI, 66% to 76%) in the RR-CHOP-14 arm (HR, 1.20; 95% CI, 0.94 to 1.55; P = .15)

282 4 arm versus 69% (95% CI, 63% to 74%) in the RR-CHOP-14 arm (HR, 1.26; 95% CI, 0.98 to 1.61; P = .07)

283 re toxicity during the first 4 cycles in the RR-CHOP-14 arm, especially neutropenia and infections.

284 without pituitary irradiation increased the RR of SAH by 4.62 (95% CI, 2.77 to 7.72).

285 astereomer remains static even at 373 K, the RR isomer shows a slow rotational process of the phenyle

286 quiring >=2 gabapentin dispensings moved the RR to 1.40 (1.03-1.90, p = 0.03) for cardiac defects.

287 f CCRT, while over the same time period, the RR was 0.85 (95% CI 0.80-0.91) in hospitals that did not

288 TR RR spectroscopy offers the advantage of simultaneously p

289 The various TR RR spectroscopic methods can cover a wide dynamic range

290 group when compared with control treatment (RR: 0.73; 95% CI: 0.53 to 1.00; p = 0.047) with a number

291 numerically lower rates after DCB treatment (RR: 0.74; 95% CI: 0.51 to 1.08; p = 0.116).

292 al [CI], 1.18-1.23), urinary antibiotic use (RR, 1.33; 95% CI, 1.28-1.38), and C. difficile infection

293 .05, p=0.93]) or income-generating time use (RR = 0.94, [CI: 0.73,1.20, p=0.61]).

294 significant effect on non-resting time use (RR = 1.00 [CI: 0.96, 1.05, p=0.93]) or income-generating

295 count >500 cell/mm3 (RR, 1.04; P = .76), VL (RR, 1.01; P = .78), and current ART class (protease inhi

296 o HCQ + AZM did not improve the VQR as well (RR = 3.23, 95% CI 0.70-14.97, I(2) = 58%).

297 lative to the control) of yield (RR(Y)), WP (RR(WP)), and NUE (RR(NUE)), respectively.

298 igher risk of death than patients <60 years (RR, 1.82; 95% CI, 1.45-2.27; N = 1169).

299 e (80.6 vs 24.2 cases per 1000 person-years; RR, 3.33; 95% CI, 1.89 to 5.85; rate difference, 56.4 ca

300 treatment relative to the control) of yield (RR(Y)), WP (RR(WP)), and NUE (RR(NUE)), respectively.